Skip to main content

Pulmonx Corp

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

LUNG$2.800.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 15. Exhibits and Financial Statement Schedules

(a) The following documents are filed as part of this Annual Report on Form 10-K:

(1) FINANCIAL STATEMENTS

Our consolidated financial statements are listed in the “Index to the Financial Statements” under Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K.

(2) FINANCIAL STATEMENT SCHEDULES

All schedules to the financial statements are omitted because they are not applicable, not material or the required information is shown in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K.

(3) EXHIBITS

The documents listed in the Exhibit Index of this Annual Report on Form 10-K are incorporated by reference or are filed with this Annual Report on Form 10-K, in each case as indicated therein.

EXHIBIT INDEX

Exhibit Number · Description of Document · Form · File No. · Exhibit · Filing Date · Filed Herewith
3.1Amended and Restated Certificate of Incorporation of Pulmonx Corporation.8-K001-395623.1October 5, 2020
3.2Amended and Restated Bylaws of Pulmonx Corporation.S-1/A333-2486353.4September 24, 2020
4.1Form of common stock certificate of Pulmonx Corporation.S-1/A333-2486354.1September 24, 2020
4.2Description of common stock of Pulmonx Corporation.10-K001-395624.3March 15, 2021
10.1+Amended and Restated 2010 Stock Plan.S-8333-24918799.1October 1, 2020
10.2+Forms of Notice of Stock Option Grant, Option Agreement, and Exercise Notice under Amended and Restated 2010 Stock Plan.S-8333-24918799.2October 1, 2020
10.3+Amended and Restated 2020 Stock Plan.S-8333-24918799.3October 1, 2020
10.4+Forms of Notice of Stock Option Grant, Option Agreement, and Exercise Notice under Amended and Restated 2020 Stock Plan.S-8333-24918799.4October 1, 2020
10.5+2020 Equity Incentive Plan.S-8333-24918799.5October 1, 2020
10.6+Forms of Option Agreement and Notice of Stock Option Grant under 2020 Equity Incentive Plan.S-8333-24918799.6October 1, 2020
10.7+Form of Restricted Stock Unit Award Agreement under 2020 Equity Incentive Plan.S-8333-24918799.7October 1, 2020
10.8+2020 Employee Stock Purchase Plan.S-8333-24918799.8October 1, 2020
10.9Form of Indemnification Agreement by and between Pulmonx Corporation and each of its directors and executive officers.S-1/A333-24863510.9September 24, 2020
10.10+Executive Employment Agreement, by and between Pulmonx Corporation and Glendon E. French, dated December 10, 2014.S-1/A333-24863510.10September 24, 2020
10.11+Offer Letter Agreement, by and between Pulmonx Corporation and Geoffrey Beran Rose, dated December 11, 2014.S-1/A333-24863510.11September 24, 2020
10.12+Offer Letter Agreement, by and between Pulmonx Corporation and Derrick Sung, Ph.D., dated March 12, 2019.S-1/A333-24863510.12September 24, 2020
10.13+Offer Letter Agreement, by and between Pulmonx Corporation and David Lehman, dated September 15, 202010-K001-3956210.13March 15, 2021
10.14Office Lease, by and between Pulmonx Corporation and HCP LS Redwood City, LLC, dated September 4, 2009.S-1/A333-24863510.18September 24, 2020
10.15First Amendment to Office Lease, by and between Pulmonx Corporation and HCP LS Redwood City, LLC, dated October 3, 2014.S-1/A333-24863510.19September 24, 2020
10.16Second Amendment to Office Lease, by and between Pulmonx Corporation and HCP LS Redwood City, LLC, dated November 7, 2019.S-1/A333-24863510.20September 24, 2020
10.17Sublease, by and between Pulmonx Corporation and Genomic Health, Inc., dated April 8, 2020.S-1/A333-24863510.21September 24, 2020
10.18First Amendment to Sublease Agreement, by and between Pulmonx Corporation and Genomic Health, Inc., dated September 10, 2020.S-1/A333-24863510.22September 24, 2020
10.19Intellectual Property Security Agreement, by and between Pulmonx Corporation and Canadian Imperial Bank of Commerce, dated February 20, 2020.S-1/A333-24863510.25September 24, 2020
10.20Note Purchase Agreement and Form of 2020 Note, by and between Pulmonx Corporation and the purchasers of the 2020 Notes, dated April 17, 2020.S-1/A333-24863510.26September 24, 2020
10.21+Pulmonx Corporation Severance and Change in Control Plan and related participation agreement.S-1/A333-24863510.27September 28, 2020
10.22Second Amendment and Waiver to Loan and Security Agreement, by and between Pulmonx Corporation and Canadian Imperial Bank of Commerce, dated December 28, 2020.10-Q001-3956210.1May 12, 2021
10.23Amended and Restated Loan and Security Agreement, by and between Pulmonx Corporation and Canadian Imperial Bank Commerce, dated March 29, 2021.10-Q001-3956210.2May 12, 2021
10.24First Amendment to Amended and Restated Loan and Security Agreement, by and between Pulmonx Corporation and Canadian Imperial Bank of Commerce, dated June 17, 2021.10-Q001-3956210.1August 10, 2021
10.25Second Amendment to Amended and Restated Loan and Security Agreement, by and between Pulmonx Corporation and Canadian Imperial Bank of Commerce, dated October 21, 2021.10-Q001-3956210.1November 9, 2021
10.26Third Amendment to Amended and Restated Loan and Security Agreement, by and between Pulmonx Corporation and Canadian Imperial Bank of Commerce, dated October 31, 2022.10-K001-3956210.27March 1, 2023
10.27+Pulmonx Corporation Amended and Restated Non-Employee Director Compensation Policy.10-Q001-3956210.1August 4, 2023
10.28Second Amendment to Sublease, by and between Pulmonx Corporation and Genomic Health, Inc., dated April 18, 2023.10-Q001-3956210.2August 4, 2023
10.29+Consulting Agreement, dated November 1, 2023, by and between Pulmonx Corporation and Derrick Sung.10-Q001-3956210.1November 3, 2023
10.30+Pulmonx Corporation Amended and Restated Non-Employee Director Compensation Policy.X
21.1List of Subsidiaries of Registrant.10-K001-3956221.1March 1, 2023
23.1Consent of BDO USA, P.C., independent registered public accounting firm.X
24.1Power of Attorney (included on signature page hereto).X
31.1Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
31.2Certification of Interim Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
32.1*Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.X
32.2*Certification of Interim Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.X
97.1Pulmonx Corporation Incentive Compensation Recoupment Policy.X
101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL documentX
101.SCHInline XBRL Taxonomy Extension Schema DocumentX
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentX
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentX
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentX
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)X
  • Indicates management contract or compensatory plan
  • The certifications attached as Exhibits 32.1 and 32.2 accompanying this Annual Report on Form 10-K are not deemed filed with the SEC and are not to be incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.